
BHC Stock Forecast & Price Target
BHC Analyst Ratings
Bulls say
Bausch Health Companies Inc. reported a positive trend in revenue growth, with Salix revenues increasing by 5% year-over-year in Q3 2024, demonstrating strong organic performance and exceeding expectations. Additionally, the company's guidance for consolidated revenues was upgraded, now projected to range between $9.500 billion and $9.675 billion, reflecting confidence in operational improvements and favorable working capital dynamics. The growth in Xifaxan prescriptions, particularly for the critical 550mg formulation used in treating hepatic encephalopathy and IBS-D, further supports the bullish outlook, with a year-over-year increase of 4.6%.
Bears say
Bausch Health Companies Inc. is facing a negative financial outlook due to a projected decline in EBITDA margins from 55% in Q3 to 48.4% in Q4, along with unfavorable foreign exchange impacts expected to reduce International Rx revenues significantly. Additionally, despite some growth anticipated in the Solta Medical segment, overall International Rx revenues are forecasted to remain flat y/y at $290 million, while ongoing operational risks, including increased competition and global geopolitical tensions, pose further threats to performance. Overall, these factors contribute to a depressed market float and diminished stock multiples, suggesting challenges ahead for the company's financial stability.
This aggregate rating is based on analysts' research of Bausch Health Companies Inc and is not a guaranteed prediction by Public.com or investment advice.
BHC Analyst Forecast & Price Prediction
Start investing in BHC
Order type
Buy in
Order amount
Est. shares
0 shares